By writer to medicaldialogues.in
Mumbai, Baltimore: Pharma main, Lupin Restricted, has just lately introduced the launch of Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg, after Lupin’s alliance accomplice Harmony Biotech Restricted acquired an approval for the corporate’s Abbreviated New Drug Software (ANDA) from america Meals and Drug Administration (USFDA).
Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg, are the generic equal of Prograf Capsules, 0.5 mg, 1 mg, and 5 mg, of Astellas Pharma US, Inc.
The product is indicated for the prophylaxis of organ rejection, in grownup sufferers receiving allogeneic kidney transplant, liver transplant, and coronary heart transplant, and in pediatric sufferers receiving allogeneic liver transplants, together with different immunosuppressants.
Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg (RLD: Prograf) had an annual gross sales of roughly USD 303 million within the U.S. (IQVIA MAT September 2020).
Learn additionally: Lupin’s supplemental new drug application for Solosec accepted by USFDA
Lupin Restricted is a worldwide pharmaceutical firm based mostly in Mumbai, Maharashtra, India.
The Firm develops and commercializes a variety of branded and generic formulations, biotechnology merchandise and APIs in over 100 markets within the U.S., India, South Africa, and throughout the Asia Pacific (APAC), Latin America (LATAM), Europe and Center-East areas.
— to medicaldialogues.in